A randomized controlled 1-year study of daily deferiprone plus twice weekly desferoxamine compared with daily deferiprone monotherapy in patients with thalassemia major

Haematologica

Volumn 92, Issue 12, 2007, Pages 1599-1606

  Aydinok, Yesim ^a   Ulger, Zulal ^a   Nart, Deniz ^a   Terzi, Aysen ^a   Cetiner, Nurten ^a   Ellis, Gareth ^b   Zimmermann, Arthur ^c   Manz, Chantal ^d  

^a EGE UNIVERSITY   (Turkey)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d Lipomed AG   (Switzerland)

Author keywords

Combination therapy; Deferiprone; Desferrioxamine; Iron balance; Iron overload; Liver iron concentration; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE;

ADOLESCENT; AGRANULOCYTOSIS; ARTICLE; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEART FUNCTION; HUMAN; IRON BALANCE; MONOTHERAPY; NEUTROPENIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR; TREATMENT DURATION; URINARY EXCRETION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON; LIVER; MALE; PYRIDONES; SIDEROPHORES; TIME FACTORS;

EID: 37049033278     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11414     Document Type: Article

References (42)

1. Grady RW, Berdoukas V, Rachmilewitz E, Galanello R, Borgna-Pignatti C, Giardina PJ. Iron chelation therapy: optimizing chelation therapy: combining deferiprone and desferrioxamine. Blood 2000;96 Suppl 1:604a[abstract].
2. Breuer W, Ermers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine chelatable iron, a component of serum non-transferrin bound iron, used for assessing chelation therapy. Blood 2001;97:792-8.
3. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-4.
4. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-87.
5. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-31.
6. Mourad FH, Hoffbrand AV, Sheikh -Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;12:187-9.
7. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassaemia major. Haematologica 2005;90:1309-14.
8. Balveer K, Pryor K, Wonke B. Combined oral and parenteral iron chelation in β thalassaemia major. Med J Malaysia 2001; 55:493-7.
9. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J 2004;5:475-9.
10. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial. Blood Cells Mol Dis 2006;36:21-5.
11. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006;85:315-9.
12. Aydinok Y, Nisli G, Kavakli K, Coker C, Kantar M, Cetingul N. Sequential use of deferiprone and desferrioxamine in primary school children with thalassemia major in Turkey. Acta Haematol 1999;102:17-21.
13. Peng CT, Wu KH, Wu SF, Liang DC, Yang CP, Jang RC, et al. Deferiprone or deferoxamine vs. combination therapy in patients with β-thalassemia major: a case study in Taiwan. Hemoglobin 2006;30:125-30.
14. Francis S, McGirr M, Browne E, Berdoukas V, Lindeman R. Efficacy of combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone in patients with thalassemia major. Blood 2003; 102:517a[abstract].
15. Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone and deferoxamine. Blood 1997;90:264a[abstract].
16. Maggio A, D'Amico G, Morabito A. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002;28:196-208.
17. Pennell DJ, Berdoukas V, Karagiorga M. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44.
18. Robbins DA. Methods for Biological Monitoring. 1988; chap 118. p. 223-7.
19. Villeneuve JP, Bilodeau M, Lepage R, Cote J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996;25:172-7.
20. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinised liver samples. S Afr J Med Sci 1968; 33: 9-11.
21. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
22. Sciot R, Van Eyken P, Facchetti F, Callea F, Van Der Steen K, Van Dijck H, et al. Hepatocellular transferrin receptor expression in secondary siderosis. Liver 1989;9:52-61.
23. American National Standards Institute. Specifications for audiometers ANSI S36-1969. New York: American National Standards Institute. 1969.
24. Modell B, Khan M, Darlison M. Survival in β-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet 2000;355:2051-2.
25. Kontoghiorghes GJ. New orally active iron chelators. Lancet 1985;1:817.
26. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al. Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 1987; 295:1509-12.
27. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-5.
28. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with β-thalassaemia major. Br J Haematol 1990;76:550-3.
29. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-9.
30. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
31. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583-7.
32. Ceci A, Biardi P, Felisi M, Capellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large-scale, 3- year study in Italian patients. Br J Haematol 2002;118:330-6.
33. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Ped 2004;41:21-7.
34. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassaemia. Blood 1997;89:739-61.
35. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron chelation therapy with oral deferiprone in patients with thalassaemia major. N Engl J Med 1995; 332:918-22.
36. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA et al. Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalassaemia major. N Engl J Med 1998;339:417-23.
37. Ha SY, Chik KW, Ling, SC, Lee AC, Luk CW, Lam CW, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006; 30:263-74.
38. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of oral iron chelator deferiprone: a multicenter study. Br J Haematol 2000;108:305-12.
39. Agarwal MP, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 1992;82:460-6.
40. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002;360: 516-20.
41. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTC, NCI, NIH, DHHS, March 31, 2003 (see http://ctep.cancer.gov), Publish date: 12 December 2003.
42. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006;91:1241-3.